Global Tissue Engineering and Organ Regeneration Market

Tissue Engineering and Organ Regeneration Comprehensive Study by Type (Tissue-engineered Products, Cell Therapies (Autologous Therapies, Allogenic Therapies), Gene Therapies, Progenitor & Stem Cell Therapies), Application (Musculoskeletal, Oncology, Wound Care, Dental, Ocular, Other Applications), End User (Hospitals, Specialty Clinics) Players and Region - Global Market Outlook to 2028

Tissue Engineering and Organ Regeneration Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Tissue Engineering and Organ Regeneration Market?

Exploring technological innovations to enhance the healthcare of the ageing and ailing populations is a global problem. Tissue engineering and regenerative medicine have steadily grown into a potential strategy to meeting future patient demands, among a variety of ways toward this objective. Tissue engineering mixes cells, scaffolds, and growth factors to regenerate or replace damaged or diseased tissues, whereas regenerative medicine combines tissue engineering with other techniques to induce tissue/organ regeneration, such as cell-based treatment, gene therapy, and immunomodulation. Every year, thousands of people die requiring organ transplant, and many more are afflicted by damaged organs. As a result of their inability to move and walk, people with spinal cord injuries face a slew of severe health difficulties. All these factors have facilitated the demand for Tissue Engineering and Organ Regeneration globally.

Highlights from Tissue Engineering and Organ Regeneration Market Study
AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledIntegra LifeSciences (United States), CryoLife Inc. (United States), LifeCell International (India), Kinetic Concepts Inc. (United States), Sanofi Genzyme (United States), Cook Biotech (United States), BioMemetic Therapeutics (United States), Osiris Therapeutics (United States), StemCells Inc (United States) and Tengion (United States)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Integra LifeSciences (United States), CryoLife Inc. (United States), LifeCell International (India), Kinetic Concepts Inc. (United States), Sanofi Genzyme (United States), Cook Biotech (United States), BioMemetic Therapeutics (United States), Osiris Therapeutics (United States), StemCells Inc (United States) and Tengion (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are NuVasive (United States), Vericel Corporation (United States) and Cytori Therapeutics (United States).

Tissue Engineering and Organ Regeneration Market Segmentation:
ScopeSub-Segments
Application / End UserMusculoskeletal, Oncology, Wound Care, Dental, Ocular and Other Applications
TypeTissue-engineered Products, Cell Therapies (Autologous Therapies, Allogenic Therapies), Gene Therapies and Progenitor & Stem Cell Therapies
End UserHospitals,Specialty Clinics


On the basis of geography, the market of Tissue Engineering and Organ Regeneration has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Emergence of Advance Treatment Procedures

Market Growth Drivers:
Prevalence of Chronic Diseases and Cancer, Increasing Array of Regenerative Medicine Products and Rising Investments in Regenerative Medicine R&D

Challenges:
Fierce Competitive Pressure and Market Penetration Across New Regions

Restraints:
Lack of Trained Professionals and Costly Procedures

Opportunities:
Growth in Healthcare Infrastructure Across Nations and Surge in Demand among Developing Regions

Key Target Audience
Tissue Engineering and Organ Regeneration Products Manufactures, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Market Leaders & Development Strategies
On 11th November, 2020 - Stryker Completed Its Acquisition of Wright Medical, Stryker's Trauma and Extremities Division Will Benefit from Wright Medical's Related Product Range and Client Base. Wright's Global Market Position in Trauma and Extremities Will Be Strengthened as A Result of This Purchase. and On 15th April, 2021 - Surrozen and Consonance-HFW Acquisition Corp. Announcd Collaboration Agreement, Surrozen's Pipeline of Lead Wnt-Modulating Antibody Products Will Be Advanced into Phase 1B With the Revenues from The Business Combination, And Pre-Clinical Research and Development Initiatives for Additional Products Will Be Continued.
On 24th February, 2020 - Integra LifeSciences Launched “AmnioExcel” Plus Placental Allograft Membrane. The New AmnioExcel Plus is A Next-Generation, Thicker, Tri-Layer, Non-Side Specific Allograft Made Up of Amnion, Chorion, And Amnion Layers That Helps to Heal Difficult Wounds.


Report Objectives / Segmentation Covered

By Type
  • Tissue-engineered Products
  • Cell Therapies (Autologous Therapies, Allogenic Therapies)
  • Gene Therapies
  • Progenitor & Stem Cell Therapies
By Application
  • Musculoskeletal
  • Oncology
  • Wound Care
  • Dental
  • Ocular
  • Other Applications
By End User
  • Hospitals
  • Specialty Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Chronic Diseases and Cancer
      • 3.2.2. Increasing Array of Regenerative Medicine Products
      • 3.2.3. Rising Investments in Regenerative Medicine R&D
    • 3.3. Market Challenges
      • 3.3.1. Fierce Competitive Pressure
      • 3.3.2. Market Penetration Across New Regions
    • 3.4. Market Trends
      • 3.4.1. Emergence of Advance Treatment Procedures
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Tissue Engineering and Organ Regeneration, by Type, Application, End User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Tissue Engineering and Organ Regeneration (Value)
      • 5.2.1. Global Tissue Engineering and Organ Regeneration by: Type (Value)
        • 5.2.1.1. Tissue-engineered Products
        • 5.2.1.2. Cell Therapies (Autologous Therapies, Allogenic Therapies)
        • 5.2.1.3. Gene Therapies
        • 5.2.1.4. Progenitor & Stem Cell Therapies
      • 5.2.2. Global Tissue Engineering and Organ Regeneration by: Application (Value)
        • 5.2.2.1. Musculoskeletal
        • 5.2.2.2. Oncology
        • 5.2.2.3. Wound Care
        • 5.2.2.4. Dental
        • 5.2.2.5. Ocular
        • 5.2.2.6. Other Applications
      • 5.2.3. Global Tissue Engineering and Organ Regeneration by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Specialty Clinics
      • 5.2.4. Global Tissue Engineering and Organ Regeneration Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Tissue Engineering and Organ Regeneration: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Integra LifeSciences (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. CryoLife Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. LifeCell International (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Kinetic Concepts Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi Genzyme (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cook Biotech (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. BioMemetic Therapeutics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Osiris Therapeutics (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. StemCells Inc (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Tengion (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Tissue Engineering and Organ Regeneration Sale, by Type, Application, End User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Tissue Engineering and Organ Regeneration (Value)
      • 7.2.1. Global Tissue Engineering and Organ Regeneration by: Type (Value)
        • 7.2.1.1. Tissue-engineered Products
        • 7.2.1.2. Cell Therapies (Autologous Therapies, Allogenic Therapies)
        • 7.2.1.3. Gene Therapies
        • 7.2.1.4. Progenitor & Stem Cell Therapies
      • 7.2.2. Global Tissue Engineering and Organ Regeneration by: Application (Value)
        • 7.2.2.1. Musculoskeletal
        • 7.2.2.2. Oncology
        • 7.2.2.3. Wound Care
        • 7.2.2.4. Dental
        • 7.2.2.5. Ocular
        • 7.2.2.6. Other Applications
      • 7.2.3. Global Tissue Engineering and Organ Regeneration by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Specialty Clinics
      • 7.2.4. Global Tissue Engineering and Organ Regeneration Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Tissue Engineering and Organ Regeneration: by Type(USD Million)
  • Table 2. Tissue Engineering and Organ Regeneration Tissue-engineered Products , by Region USD Million (2017-2022)
  • Table 3. Tissue Engineering and Organ Regeneration Cell Therapies (Autologous Therapies, Allogenic Therapies) , by Region USD Million (2017-2022)
  • Table 4. Tissue Engineering and Organ Regeneration Gene Therapies , by Region USD Million (2017-2022)
  • Table 5. Tissue Engineering and Organ Regeneration Progenitor & Stem Cell Therapies , by Region USD Million (2017-2022)
  • Table 6. Tissue Engineering and Organ Regeneration: by Application(USD Million)
  • Table 7. Tissue Engineering and Organ Regeneration Musculoskeletal , by Region USD Million (2017-2022)
  • Table 8. Tissue Engineering and Organ Regeneration Oncology , by Region USD Million (2017-2022)
  • Table 9. Tissue Engineering and Organ Regeneration Wound Care , by Region USD Million (2017-2022)
  • Table 10. Tissue Engineering and Organ Regeneration Dental , by Region USD Million (2017-2022)
  • Table 11. Tissue Engineering and Organ Regeneration Ocular , by Region USD Million (2017-2022)
  • Table 12. Tissue Engineering and Organ Regeneration Other Applications , by Region USD Million (2017-2022)
  • Table 13. Tissue Engineering and Organ Regeneration: by End User(USD Million)
  • Table 14. Tissue Engineering and Organ Regeneration Hospitals , by Region USD Million (2017-2022)
  • Table 15. Tissue Engineering and Organ Regeneration Specialty Clinics , by Region USD Million (2017-2022)
  • Table 16. South America Tissue Engineering and Organ Regeneration, by Country USD Million (2017-2022)
  • Table 17. South America Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 18. South America Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 19. South America Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 20. Brazil Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 21. Brazil Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 22. Brazil Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 23. Argentina Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 24. Argentina Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 25. Argentina Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 26. Rest of South America Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 27. Rest of South America Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 28. Rest of South America Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 29. Asia Pacific Tissue Engineering and Organ Regeneration, by Country USD Million (2017-2022)
  • Table 30. Asia Pacific Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 31. Asia Pacific Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 32. Asia Pacific Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 33. China Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 34. China Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 35. China Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 36. Japan Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 37. Japan Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 38. Japan Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 39. India Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 40. India Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 41. India Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 42. South Korea Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 43. South Korea Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 44. South Korea Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 45. Taiwan Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 46. Taiwan Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 47. Taiwan Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 48. Australia Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 49. Australia Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 50. Australia Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 53. Rest of Asia-Pacific Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 54. Europe Tissue Engineering and Organ Regeneration, by Country USD Million (2017-2022)
  • Table 55. Europe Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 56. Europe Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 57. Europe Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 58. Germany Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 59. Germany Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 60. Germany Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 61. France Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 62. France Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 63. France Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 64. Italy Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 65. Italy Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 66. Italy Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 67. United Kingdom Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 68. United Kingdom Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 69. United Kingdom Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 70. Netherlands Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 71. Netherlands Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 72. Netherlands Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 73. Rest of Europe Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 74. Rest of Europe Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 75. Rest of Europe Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 76. MEA Tissue Engineering and Organ Regeneration, by Country USD Million (2017-2022)
  • Table 77. MEA Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 78. MEA Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 79. MEA Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 80. Middle East Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 81. Middle East Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 82. Middle East Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 83. Africa Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 84. Africa Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 85. Africa Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 86. North America Tissue Engineering and Organ Regeneration, by Country USD Million (2017-2022)
  • Table 87. North America Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 88. North America Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 89. North America Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 90. United States Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 91. United States Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 92. United States Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 93. Canada Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 94. Canada Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 95. Canada Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 96. Mexico Tissue Engineering and Organ Regeneration, by Type USD Million (2017-2022)
  • Table 97. Mexico Tissue Engineering and Organ Regeneration, by Application USD Million (2017-2022)
  • Table 98. Mexico Tissue Engineering and Organ Regeneration, by End User USD Million (2017-2022)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Tissue Engineering and Organ Regeneration: by Type(USD Million)
  • Table 110. Tissue Engineering and Organ Regeneration Tissue-engineered Products , by Region USD Million (2023-2028)
  • Table 111. Tissue Engineering and Organ Regeneration Cell Therapies (Autologous Therapies, Allogenic Therapies) , by Region USD Million (2023-2028)
  • Table 112. Tissue Engineering and Organ Regeneration Gene Therapies , by Region USD Million (2023-2028)
  • Table 113. Tissue Engineering and Organ Regeneration Progenitor & Stem Cell Therapies , by Region USD Million (2023-2028)
  • Table 114. Tissue Engineering and Organ Regeneration: by Application(USD Million)
  • Table 115. Tissue Engineering and Organ Regeneration Musculoskeletal , by Region USD Million (2023-2028)
  • Table 116. Tissue Engineering and Organ Regeneration Oncology , by Region USD Million (2023-2028)
  • Table 117. Tissue Engineering and Organ Regeneration Wound Care , by Region USD Million (2023-2028)
  • Table 118. Tissue Engineering and Organ Regeneration Dental , by Region USD Million (2023-2028)
  • Table 119. Tissue Engineering and Organ Regeneration Ocular , by Region USD Million (2023-2028)
  • Table 120. Tissue Engineering and Organ Regeneration Other Applications , by Region USD Million (2023-2028)
  • Table 121. Tissue Engineering and Organ Regeneration: by End User(USD Million)
  • Table 122. Tissue Engineering and Organ Regeneration Hospitals , by Region USD Million (2023-2028)
  • Table 123. Tissue Engineering and Organ Regeneration Specialty Clinics , by Region USD Million (2023-2028)
  • Table 124. South America Tissue Engineering and Organ Regeneration, by Country USD Million (2023-2028)
  • Table 125. South America Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 126. South America Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 127. South America Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 128. Brazil Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 129. Brazil Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 130. Brazil Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 131. Argentina Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 132. Argentina Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 133. Argentina Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 134. Rest of South America Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 135. Rest of South America Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 136. Rest of South America Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 137. Asia Pacific Tissue Engineering and Organ Regeneration, by Country USD Million (2023-2028)
  • Table 138. Asia Pacific Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 139. Asia Pacific Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 140. Asia Pacific Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 141. China Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 142. China Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 143. China Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 144. Japan Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 145. Japan Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 146. Japan Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 147. India Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 148. India Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 149. India Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 150. South Korea Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 151. South Korea Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 152. South Korea Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 153. Taiwan Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 154. Taiwan Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 155. Taiwan Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 156. Australia Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 157. Australia Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 158. Australia Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 159. Rest of Asia-Pacific Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 160. Rest of Asia-Pacific Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 161. Rest of Asia-Pacific Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 162. Europe Tissue Engineering and Organ Regeneration, by Country USD Million (2023-2028)
  • Table 163. Europe Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 164. Europe Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 165. Europe Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 166. Germany Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 167. Germany Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 168. Germany Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 169. France Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 170. France Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 171. France Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 172. Italy Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 173. Italy Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 174. Italy Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 175. United Kingdom Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 176. United Kingdom Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 177. United Kingdom Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 178. Netherlands Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 179. Netherlands Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 180. Netherlands Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 181. Rest of Europe Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 182. Rest of Europe Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 183. Rest of Europe Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 184. MEA Tissue Engineering and Organ Regeneration, by Country USD Million (2023-2028)
  • Table 185. MEA Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 186. MEA Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 187. MEA Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 188. Middle East Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 189. Middle East Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 190. Middle East Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 191. Africa Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 192. Africa Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 193. Africa Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 194. North America Tissue Engineering and Organ Regeneration, by Country USD Million (2023-2028)
  • Table 195. North America Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 196. North America Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 197. North America Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 198. United States Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 199. United States Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 200. United States Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 201. Canada Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 202. Canada Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 203. Canada Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 204. Mexico Tissue Engineering and Organ Regeneration, by Type USD Million (2023-2028)
  • Table 205. Mexico Tissue Engineering and Organ Regeneration, by Application USD Million (2023-2028)
  • Table 206. Mexico Tissue Engineering and Organ Regeneration, by End User USD Million (2023-2028)
  • Table 207. Research Programs/Design for This Report
  • Table 208. Key Data Information from Secondary Sources
  • Table 209. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Tissue Engineering and Organ Regeneration: by Type USD Million (2017-2022)
  • Figure 5. Global Tissue Engineering and Organ Regeneration: by Application USD Million (2017-2022)
  • Figure 6. Global Tissue Engineering and Organ Regeneration: by End User USD Million (2017-2022)
  • Figure 7. South America Tissue Engineering and Organ Regeneration Share (%), by Country
  • Figure 8. Asia Pacific Tissue Engineering and Organ Regeneration Share (%), by Country
  • Figure 9. Europe Tissue Engineering and Organ Regeneration Share (%), by Country
  • Figure 10. MEA Tissue Engineering and Organ Regeneration Share (%), by Country
  • Figure 11. North America Tissue Engineering and Organ Regeneration Share (%), by Country
  • Figure 12. Global Tissue Engineering and Organ Regeneration share by Players 2022 (%)
  • Figure 13. Global Tissue Engineering and Organ Regeneration share by Players (Top 3) 2022(%)
  • Figure 14. Global Tissue Engineering and Organ Regeneration share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Integra LifeSciences (United States) Revenue, Net Income and Gross profit
  • Figure 17. Integra LifeSciences (United States) Revenue: by Geography 2022
  • Figure 18. CryoLife Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. CryoLife Inc. (United States) Revenue: by Geography 2022
  • Figure 20. LifeCell International (India) Revenue, Net Income and Gross profit
  • Figure 21. LifeCell International (India) Revenue: by Geography 2022
  • Figure 22. Kinetic Concepts Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Kinetic Concepts Inc. (United States) Revenue: by Geography 2022
  • Figure 24. Sanofi Genzyme (United States) Revenue, Net Income and Gross profit
  • Figure 25. Sanofi Genzyme (United States) Revenue: by Geography 2022
  • Figure 26. Cook Biotech (United States) Revenue, Net Income and Gross profit
  • Figure 27. Cook Biotech (United States) Revenue: by Geography 2022
  • Figure 28. BioMemetic Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 29. BioMemetic Therapeutics (United States) Revenue: by Geography 2022
  • Figure 30. Osiris Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 31. Osiris Therapeutics (United States) Revenue: by Geography 2022
  • Figure 32. StemCells Inc (United States) Revenue, Net Income and Gross profit
  • Figure 33. StemCells Inc (United States) Revenue: by Geography 2022
  • Figure 34. Tengion (United States) Revenue, Net Income and Gross profit
  • Figure 35. Tengion (United States) Revenue: by Geography 2022
  • Figure 36. Global Tissue Engineering and Organ Regeneration: by Type USD Million (2023-2028)
  • Figure 37. Global Tissue Engineering and Organ Regeneration: by Application USD Million (2023-2028)
  • Figure 38. Global Tissue Engineering and Organ Regeneration: by End User USD Million (2023-2028)
  • Figure 39. South America Tissue Engineering and Organ Regeneration Share (%), by Country
  • Figure 40. Asia Pacific Tissue Engineering and Organ Regeneration Share (%), by Country
  • Figure 41. Europe Tissue Engineering and Organ Regeneration Share (%), by Country
  • Figure 42. MEA Tissue Engineering and Organ Regeneration Share (%), by Country
  • Figure 43. North America Tissue Engineering and Organ Regeneration Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Integra LifeSciences (United States)
  • CryoLife Inc. (United States)
  • LifeCell International (India)
  • Kinetic Concepts Inc. (United States)
  • Sanofi Genzyme (United States)
  • Cook Biotech (United States)
  • BioMemetic Therapeutics (United States)
  • Osiris Therapeutics (United States)
  • StemCells Inc (United States)
  • Tengion (United States)
Additional players considered in the study are as follows:
NuVasive (United States) , Vericel Corporation (United States) , Cytori Therapeutics (United States)
Select User Access Type

Key Highlights of Report


Jul 2023 222 Pages 82 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Tissue Engineering and Organ Regeneration Market Quantitative research analysis
Global Tissue Engineering and Organ Regeneration Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Prevalence of Chronic Diseases and Cancer " is seen as one of major growth factors of Tissue Engineering and Organ Regeneration Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
The Tissue Engineering and Organ Regeneration market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Tissue Engineering and Organ Regeneration Market Report?

Have a Query? Click Here

Other Related Reports

Somatic Genetic Testing Comprehensive Study by Type (Product (Kits and Assays, Instruments, and Software), Services), Application (Solid Tumors (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lun...
$ 3750
Minichromosomal Technology Comprehensive Study by Type (Reagents & Consumables, Software & Systems, Services), Application (Cell Line Engineering, Genetic Engineering, Diagnostic Applications, Drug D...
$ 3650
Home Insemination Products Comprehensive Study by Type (Insemination Kits, Home Conception Devices, Accessories), Distribution Channel (Online, Offline), End User (Hospitals &Clinics, Fertility Centr...
$ 3500
Pulmonary Fibrosis Drug Comprehensive Study by Drug (Pirfenidone, Nintedanib, Others), Form (Pills, Solutions, Tablets, Others), Distribution (Hospital Dispensaries, Retail Pharmacies, Third Party On...
$ 3500
Anti-CD19 Comprehensive Study by Type (Antibody Drug Conjugates, Chimeric Antigen Receptor (CAR) T-Cell Therapy (CAR-T Therapies), Engineered Antibodies, Bispecific Antibody (BsAb)), Application (Hos...
$ 3350
Tool Enzyme Comprehensive Study by Application (Nucleic Acid Amplification Testing, Protein and Small Molecule Detection, Other), Category (DNA Restriction Endonuclease, Ligase, Polymerase, Nuclease,...
$ 3450